2019
Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity
Dearborn JL, Viscoli CM, Young LH, Gorman MJ, Furie KL, Kernan WN. Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. Stroke 2019, 50: 713-717. PMID: 30786849, PMCID: PMC6391736, DOI: 10.1161/strokeaha.118.024008.Peer-Reviewed Original ResearchConceptsTransient ischemic attackBody mass indexProportion of patientsIschemic strokeMass indexVascular eventsBaseline weightWeight lossAchievement of guidelineDays of randomizationRecent ischemic strokeAcute ischemic strokeFuture vascular eventsIschemic attackPlacebo groupObese patientsDiabetes mellitusMedian ageTrial entryIRIS trialMedian timeFunctional outcomeInsulin resistanceClinical trialsPatients
2016
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial
Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN, Investigators F. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. The Journal Of Clinical Endocrinology & Metabolism 2016, 102: 914-922. PMID: 27935736, PMCID: PMC5460686, DOI: 10.1210/jc.2016-3237.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokeFracture riskBone fracturesRisk/benefit ratioAbsolute fracture riskInsulin Resistance InterventionPlacebo-treated patientsIschemic attackNondiabetic patientsPlacebo groupCardiovascular riskBone healthStroke trialsNondiabetic participantsPrevent fallsClinical trialsRelative riskSafety dataFracture classificationQuarterly interviewsPioglitazonePatientsResistance InterventionRisk increment
2011
Boosting enrolment in clinical trials: validation of a regional network model
Kernan W, Viscoli C, Brass L, Amatangelo M, Birch A, Clark W, Conwit R, Furie K, Gorman M, Pesapane B, Kleindorfer D, Lovejoy A, Osborne J, Silliman S, Zweifler R, Horwitz R. Boosting enrolment in clinical trials: validation of a regional network model. Clinical Trials 2011, 8: 645-653. PMID: 21824978, PMCID: PMC3852692, DOI: 10.1177/1740774511414925.Peer-Reviewed Original ResearchConceptsClinical trialsTransient ischemic attackNames of patientsEligible patientsIschemic attackStroke preventionDrug adherenceStroke therapyActive surveillanceAverage monthly rateHome visitsPatientsHospitalTrial researchParticipant costsOutreach NetworkMultiple hospitalsTrialsStudy intervalNational InstituteEnrollmentMonthly rateStrokeParticipantsReproducible method
2010
What Is the Future of Stroke Prevention?
Kernan WN, Launer LJ, Goldstein LB. What Is the Future of Stroke Prevention? Stroke 2010, 41: s35-s38. PMID: 20876501, PMCID: PMC4795938, DOI: 10.1161/strokeaha.110.592022.Peer-Reviewed Original ResearchConceptsRisk factorsPolypill approachDrug-related side effectsCardiovascular risk factorsFirst ischemic strokeStroke risk factorsMultiple risk factorsOlder adult populationStroke preventionIschemic strokeBlood pressureCholesterol levelsClinical trialsSide effectsAdult populationPolypillStrokeEntire populationRiskLarge populationPopulationCertain ageMedicationsPharmacodynamicsPharmacokinetics
2005
Altruism as a reason for participation in clinical trials was independently associated with adherence
Rosenbaum JR, Wells CK, Viscoli CM, Brass LM, Kernan WN, Horwitz RI. Altruism as a reason for participation in clinical trials was independently associated with adherence. Journal Of Clinical Epidemiology 2005, 58: 1109-1114. PMID: 16223653, DOI: 10.1016/j.jclinepi.2005.03.014.Peer-Reviewed Original ResearchConceptsClinical trialsBetter functional statusStudy medicationMedical regimenRecruitment of participantsClinical featuresStroke trialsFunctional statusWomen's EstrogenStratified analysisMultivariable regressionClinical researchEstrogenTrialsAdherenceBaseline featuresSocial supportFurther investigationWomenParticipantsAltruistic reasonsPossible contributionHigh levelsPlaceboMedicationsDecline in Physical Performance Among Women With a Recent Transient Ischemic Attack or Ischemic Stroke
Kernan WN, Viscoli CM, Brass LM, Gill TM, Sarrel PM, Horwitz RI. Decline in Physical Performance Among Women With a Recent Transient Ischemic Attack or Ischemic Stroke. Stroke 2005, 36: 630-634. PMID: 15677573, DOI: 10.1161/01.str.0000155728.42847.de.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokePhysical performance testsPhysical performanceIschemic attackRecent transient ischemic attackRecent ischemic strokeRecurrent neurological eventsAbsence of recurrenceLong-term disabilityEstrogen therapyRecurrent strokePostmenopausal womenNeurological eventsClinical trialsPPT scoresBaseline scoresFunctional independenceStrokeSpecific interventionsSubsequent strokeWomenSustained declineScoresBaseline
2003
Influence of race, clinical, and other socio-demographic features on trial participation
Corbie-Smith G, Viscoli CM, Kernan WN, Brass LM, Sarrel P, Horwitz RI. Influence of race, clinical, and other socio-demographic features on trial participation. Journal Of Clinical Epidemiology 2003, 56: 304-309. PMID: 12767406, DOI: 10.1016/s0895-4356(03)00046-5.Peer-Reviewed Original ResearchConceptsTrial participationPrevious estrogen useClinical trial participationHistory of hysterectomyEstrogen useClinical characteristicsStroke trialsWomen's EstrogenClinical trialsConsent ratesCognitive impairmentSocio-demographic featuresMultivariate modelInfluence of raceHysterectomyEstrogenWomen's decisionsTrialsEthnic groupsImpairmentVisitsWomen
2001
A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli C, Brass L, Kernan W, Sarrel P, Suissa S, Horwitz R. A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke. New England Journal Of Medicine 2001, 345: 1243-1249. PMID: 11680444, DOI: 10.1056/nejmoa010534.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyEstrogen therapyNonfatal strokePostmenopausal womenIschemic strokeCerebrovascular diseasePlacebo-controlled trialTransient ischemic attackOccurrence of strokeRisk of deathIschemic attackFatal strokeMean followPlacebo groupSecondary preventionEstradiol groupFunctional deficitsClinical trialsObservational studyHigh riskWoman's riskTherapyStrokeWomenDeath
1999
Stratified Randomization for Clinical Trials
Kernan W, Viscoli C, Makuch R, Brass L, Horwitz R. Stratified Randomization for Clinical Trials. Journal Of Clinical Epidemiology 1999, 52: 19-26. PMID: 9973070, DOI: 10.1016/s0895-4356(98)00138-3.Peer-Reviewed Original ResearchConceptsStratified randomizationSmall trialsInterim analysisActive-control equivalence trialsClinical factorsLarge trialsSuperiority trialSubgroup analysisClinical trialsTreatment responsivenessTreatment outcomesMEDLINE searchTreatment groupsStratification factorsEquivalence trialPrognosisTrialsRandomizationType ITheoretical benefitsImportance of stratificationStratificationSample sizeInvestigatorsPatients
1989
Ceftriaxone Compared with Cefotaxime for Serious Bacterial Infections
Smith C, Petty B, Hendrix C, Kernan W, Garver P, Fox K, Beamer A, Carbone K, Threlkeld M, Lietman P. Ceftriaxone Compared with Cefotaxime for Serious Bacterial Infections. The Journal Of Infectious Diseases 1989, 160: 442-447. PMID: 2668428, DOI: 10.1093/infdis/160.3.442.Peer-Reviewed Original ResearchConceptsSerious bacterial infectionsBacterial infectionsDouble-blind clinical trialSuspected serious bacterial infectionResponse rateCefotaxime 2 gCeftriaxone 2 gDose of ceftriaxoneTreatment groupsDose of cefotaximeFrequency of diarrheaClinical responseAnaerobic infectionsProthrombin timeCeftriaxoneClinical trialsCefotaximeInfecting organismInfectionAdverse effectsDoseTreatmentDaysThrombophlebitisProthrombin